Ọrịa cancer pancreatic: Nhọrọ ọgwụgwọ ọhụrụ

N'ọgụ megide ọrịa kansa pancreatic, nnwale ụlọ ọgwụ ọhụrụ na nke ọhụrụ adịla oke egwu. Ọnwụnwa ndị a na-enye ndị ọrịa ohere n'oge na-enweta ọgwụgwọ dị oke ọnụ nke nwere ike iduga ọganihu na nyocha na olileanya maka nsonaazụ ka mma. 

Achọpụtara ọgwụgwọ ọ bụla dị taa na mbụ, mepụta ma kwado ya site na nnwale ụlọ ọgwụ - nyocha nyocha nke na-enyocha ọgwụgwọ ọhụrụ ma ọ bụ ngwakọta nke ọgwụgwọ dị ugbu a iji chọpụta ma ọ bara uru nye ndị nwere ọrịa kansa pancreatic. Ọrịa cancer pancreatic na-aghọwanye ihe na-akpata nchegbu zuru ụwa ọnụ, na-ebute mkpa ọ dị maka ọgwụgwọ ọhụrụ na mbọ mmepe ọgwụ. Mkpa a na-egbobeghị nke metụtara ọrịa ahụ na-adọta ọtụtụ ụlọ ọrụ mba dị iche iche itinye ego na ụlọ ọrụ ahụ. Ihe ndị a jikọtara yana ịrị elu mmefu nlekọta ahụike n'ụwa niile ga-abawanye uto ahịa. Otu akụkọ sitere na Global Market Insight kwuru na a na-atụ anya nha ahịa ọgwụgwọ ọrịa ọrịa Pancreatic ga-eweta nnukwu ego n'afọ 2021 ruo 2027. Akuko ahụ gara n'ihu: “A na-ahụta ọrịa kansa pancreatic dị ka otu n'ime ụdị ọrịa kansa kachasị ike nke sitere na anụ ahụ pancreatic ma nwee ike ngwa ngwa. gbasaa na akụkụ ahụ dị nso. Nhọrọ ibi ndụ na-adịghị mma dị ka ise siga, mmanya na-aba n'anya na ịṅụ sịga yana ọrịa ndị metụtara ndụ dị ka oke ibu na ọrịa shuga so na isi ihe na-ebute ọrịa kansa pancreatic. Òtù Na-ahụ Maka Ọrịa Cancer nke America na-eme atụmatụ na a ga-achọpụta ihe karịrị ndị America 60,000 nwere ọrịa cancer pancreatic na 2021. A na-ahụkwa usoro ndị yiri nke ahụ n'ọtụtụ akụkụ ụwa ndị ọzọ nke ga-eme ka usoro ụlọ ọrụ dịkwuo elu." Ụlọ ọrụ biotech na ọgwụ na-arụ ọrụ n'ahịa n'izu a gụnyere Oncolytics Biotech® Inc., Bristol Myers Squibb, Seagen Inc., Exact Sciences Corp., Kura Oncology, Inc.

Global Market Insight gbakwụnyere, sị: “Chemotherapy, immunotherapy, ọgwụgwọ ezubere iche, na ọgwụgwọ homonụ, n'etiti ndị ọzọ, bụ ụdị nhọrọ ọgwụgwọ ọrịa kansa pancreatic dị iche iche. N'ime ndị a, akụkụ ọgwụgwọ ezubere iche nwere ike weghara oke ahịa ahịa ka ọ na-erule 2027. Usoro ọgwụgwọ ezubere iche lekwasịrị anya na protein, mkpụrụ ndụ ihe nketa, ma ọ bụ anụ ahụ nke ọrịa kansa na-enye aka na uto nke ọrịa kansa. Ọgwụgwọ na-egbochi uto na mgbasa nke mkpụrụ ndụ kansa ma na-egbochi mmebi nke ndị ahụ dị mma. Usoro ọgwụgwọ ezubere iche ga-achọpụta mmụba nke ọgwụgwọ ọrịa kansa pancreatic n'afọ ndị na-abịa. ”

Oncolytics Biotech® na-enye mmelite nchekwa dị mma na Òtù Na-ahụ Maka Ọrịa Ọrịa Pancreatic nke Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial - Oncolytics Biotech® ) taa kwupụtara mmezu nke ọma nke nchekwa nchekwa ndị ọrịa atọ na-agba ọsọ maka otu ọrịa cancer pancreatic nke pancreatic. Nkeji 1/2 GOBLET ọmụmụ na-eso nleba anya site na data Safety Monitoring Board (DSMB). DSMB ahụghị nchegbu nchekwa ọ bụla na ndị ọrịa a ma tụọ aro ka ọmụmụ ihe ahụ gaa n'ihu dịka akwadoro. Ntinye nchekwa maka ndị otu ọrịa kansa metastatic colorectal nke atọ a ka na-aga n'ihu.

AIO, otu ndị isi agụmakwụkwọ na-akwado oncology oncology nke dị na Germany na-elekọta ọmụmụ ihe GOBLET, ma emebere ya iji nyochaa nchekwa na arụmọrụ nke pelareorep yana Roche's anti-PD-L1 checkpoint inhibitor atezolizumab n'ime ndị ọrịa nwere pancreatic metastatic, metastatic. colorectal, na ọrịa kansa gbasara gbasara ike. Ọmụmụ ihe a ka na-aga n'ihu ma na-atụ anya ịdebanye aha ndị ọrịa na saịtị ikpe ụlọ ọgwụ 14 n'ofe Germany.

Ndị otu ọrịa cancer pancreatic nke ọmụmụ GOBLET gbatịkwuru data ụlọ ọgwụ na-egosi mmekọrịta na mgbochi ọrịa kansa nke pelareorep yana mgbochi nyocha nke ndị ọrịa kansa pancreatic bụ ndị gara n'ihu mgbe ọgwụgwọ mbụ gasịrị (njikọ PR, njikọ na akwụkwọ mmado). Ọ na-ewuli elu na data ụlọ ọgwụ mbụ nke gosipụtara mmụba karịrị 80% na ndụ na-enweghị ọganihu na-aga n'ihu na ndị ọrịa cancer pancreatic nwere obere ọkwa CEACAM6 bụ ndị natara pelareorep na ngwakọta na chemotherapy (njikọ na PR, njikọ na akwụkwọ mmado). Na mgbakwunye na nyochaa nchekwa na ịdị irè nke ọgwụgwọ pelareorep-atezolizumab, GOBLET na-achọkwa igosi ikike nke CEACAM6 na T cell clonality dị ka ndị na-ebu amụma amụma, nke nwere ike ime ka ohere nke ịga nke ọma nke akwụkwọ ndebanye aha n'ọdịnihu site n'ikwe ka nhọrọ nke ndị ọrịa kwesịrị ekwesị. .  

Seagen Inc. kwuputara data na nso nso a sitere na nnwale ụlọ ọgwụ na-agbakọ SEA-CD1 na chemotherapy yana mgbochi PD-40 na ndị ọrịa nwere PDAC metastatic na nzukọ kwa afọ ASCO GI na-ewere ọnọdụ na San Francisco, Jenụwarị 1 – 20, 22. SEA -CD2022 bụ akwụkwọ akụkọ, nyocha, nonfucosylated monoclonal receptor-agonist antibody na-eduzi CD40, nke egosipụtara na sel ndị na-eweta antigen. N'ụdị preclinical, nchikota nke SEA-CD40 na chemotherapy rụpụtara ọrụ antitumor nke ejiri ọgwụgwọ mgbochi PD-40 kwalitewanye.

N'ime usoro 1 na-aga n'ihu, SEA-CD40 jikọtara ya na chemotherapy [gemcitabine na nab-paclitaxel (GnP)], na mgbochi PD-1 (pembrolizumab), na ndị ọrịa 61 na-enweghị ọgwụgwọ PDAC. N'ime ndị a, ndị ọrịa 40 natara 10 mcg / kg na ndị ọrịa 21 natara 30 mcg / kg nke SEA-CD40. Isi njedebe gụnyere ọnụego nzaghachi ebumnobi ekwenyesiri ike (cORR) kwa RECIST v1.1 site n'aka onye nyocha, nlanarị na-enweghị ọganihu (PFS) na nlanarị n'ozuzu (OS) "Ọrụ mbụ na-agba ume dabere na nsonaazụ chemotherapy akụkọ ihe mere eme. Achọrọ nleba anya ọzọ iji mee ka usoro anyị na-esote maka ọrịa kansa pancreatic, "Roger Dansey, MD, Chief Medical Officer na Seagen kwuru. "Anyị na-aga n'ihu na-aga n'ihu na-aga n'ihu na-aga n'ihu na usoro 2 nke SEA-CD40 na melanoma na ọrịa cancer akpa ume na-abụghị obere cell."

Exact Sciences Corp. kwuputara data arụmọrụ n'oge na-adịbeghị anya maka ule Cologuard ọgbọ nke abụọ (ọtụtụ stool DNA) na-egosi nhụsianya zuru oke nke 95.2% maka ọrịa cancer colorectal (CRC) na kpọmkwem 92.4% maka nlele na-adịghị mma nke colonoscopy kwadoro. Ntụle otu n'okpuru gosiri 83.3% uche maka dysplasia ọkwa dị elu, ọnya precancer kacha dị ize ndụ, yana 57.2% maka ọnya ọnya niile dị elu. A ga-ewepụta data ndị a Jenụwarị 22 na ASCO GI na akwụkwọ mmado akpọrọ, “Ọgbọ nke Abụọ Multi-Target Stool DNA Panel Na-achọpụta Ọrịa Cancer Na-ahụ Maka Ọrịa Na-ahụ Maka Ọrịa Cancer na Ọnya Ọdịnaya Dị elu.”

Cologuard bụ nke mbụ na naanị FDA kwadoro, ule DNA na-adịghị emerụ ahụ nke ejiri enyocha ndị nwere ihe ize ndụ maka CRC. Kpọmkwem Sayensị na-etolite Cologuard ọgbọ nke abụọ iji melite nkọwapụta na precancer uche nke ule ahụ, na-ebelata ọnụego adịgboroja adịgboroja yana ịbawanye ọnụego nchọpụta nke ọnya ndị nwere ọrịa kansa. Ọmụmụ ihe ahụ na-egosi ikike nke otu panel nke ịkpa oke oke nke akara DNA methylated na haemoglobin fecal iji mezuo ma n'ọnọdụ ụwa n'ezie. Ọ bụrụ na akwadoro ya, ule Cologuard nke ọgbọ nke abụọ nwere ike inye aka ịbawanye ọnụego nyocha ma na-eziga mmadụ ole na ole ka ha na-agbaso colonoscopies na-enweghị isi na ịchọpụta ndị na-ebute ọrịa cancer tupu ha enwee ọganihu na ọrịa cancer, na-enyere aka igbochi ọrịa ahụ.

N'oge na-adịbeghị anya Bristol Myers Squibb kwupụtara kọmitii maka ngwaahịa ọgwụ maka ojiji mmadụ (CHMP) nke European Medicine Agency (EMA) akwadoro nkwado nke Breyanzi (lisocabtagene maraleucel; liso-cel), sel T nke chimeric antigen (CAR) na-eduzi CD19. ọgwụgwọ maka ọgwụgwọ nke ndị okenye nwere nlọghachi azụ ma ọ bụ refractory (R/R) na-agbasa nnukwu lymphoma B-cell (DLBCL), isi mgbasa ozi nnukwu B-cell lymphoma (PMBCL), na follicular lymphoma grade 3B (FL3B) mgbe ahịrị abụọ ma ọ bụ karịa. nke usoro ọgwụgwọ. European Commission (EC) ga-enyocha ndụmọdụ CHMP ugbu a, nke nwere ikike ịkwado ọgwụ maka European Union (EU).

Kura Oncology, Inc., ụlọ ọrụ biopharmaceutical nke ụlọ ọgwụ na-agba mbọ imezu nkwa nke ọgwụ ziri ezi maka ọgwụgwọ ọrịa kansa, kwupụtara n'oge na-adịbeghị anya na US Food and Drug Administration (FDA) ebulila njide ụlọ ọgwụ na KOMET-001 Phase. 1b ọmụmụ nke KO-539 na ndị ọrịa nwere nlọghachi azụ ma ọ bụ refractory nnukwu myeloid leukemia (AML). Ebuliri njide ụlọ ọgwụ ahụ na-esochi nkwekọrịta ya na FDA na atụmatụ mbelata nke ụlọ ọrụ maka ọrịa dị iche iche, ihe omume ọjọọ amaara nke metụtara ndị na-ahụ maka ndịiche na ọgwụgwọ AML.